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ABSTRACT 
Rheumatoid Arthritis (RA) is a severe autoimmune disease affecting 0.5-1% worldwide. 
Patients suffer from pain, disability, chronic joint inflammation, comorbidities and increased 
mortality. Although, the aetiology of RA is largely unknown, both genes and environment 
have been shown to contribute. The major risk factors of RA, smoking and HLA-DRB1 
shared epitope (SE) alleles, associate primarily with the presence of autoantibodies to 
citrullinated proteins (ACPA). These antibodies are present in two thirds of patients, precede 
clinical symptoms, and predict a more destructive disease course. However, the exact trigger 
of ACPA production remains unclear. In addition to smoking, periodontitis (PD) has been 
epidemiologically linked to RA. Both smoking and PD cause local inflammation and 
increased protein citrullination. Moreover, Porphyromonas gingivalis (P.gin) - the keystone 
pathogen in chronic PD - is the only known prokaryote to express an enzyme that can 
citrullinate polypeptides (peptidyl arginine deiminase, denoted P.PAD). With this unique 
property, it was suggested that P.PAD could generate citrullinated epitopes in the inflamed 
periodontium, which would trigger a systemic ACPA response that eventually cause 
intraarticular inflammation. Based on this hypothesis, the overall aim of my PhD project was 
to investigate the role of Porphyromonas gingivalis in the aetiology of ACPA-positive RA, in 
terms of ACPA production, association with classical risk factors, and disease progression. 
Most studies in this thesis were performed in the population-based RA case-control cohort 
EIRA, where serum samples and information on genes (i.e. SE and PTPN22 polymorphism) 
and smoking history were available. In Study I, we showed that classical RA risk factors 
associated with specific ACPAs rather than the magnitude of the ACPA response, suggesting 
that the production of different ACPA fine-specificities is governed by partly different 
mechanisms. In Study II, we identified an association between anti-P.gin antibodies and RA 
(in particular ACPA-positive RA) that was even stronger than the association between 
smoking and RA. Moreover, we observed interactions between anti-P.gin antibodies and both 
SE and smoking in ACPA-positive RA. With Study III, we could demonstrate that anti-P.gin 
antibodies pre-dated clinical RA with up to 12 years. Study IV revealed a citrulline-specific 
antibody response to a P.PAD epitope in non-RA PD patients. Moreover, we identified a 
monoclonal antibody derived from RA blood, which exhibited cross-reactivity between 
citrullinated epitopes on bacterial (P.PAD) and human (vimentin) proteins.  
The data presented in this PhD thesis support a role for P.gin in the development of ACPA-
positive RA, and we propose that the pathway involves citrullination by P.PAD, followed by 
an antibody response, which cross-reacts with citrullinated human proteins, and that 
expansion of the autoimmune ACPA response in genetically susceptible individuals 
eventually triggers RA. It is my hope that the data presented herein can serve as a basis for 
disease-preventive strategies, as well as more detailed studies of disease mechanisms in RA 
aetiopathogenesis, ultimately aimed at the development of curative therapies.   
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1 INTRODUCTION  
1.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a heterogeneous chronic inflammatory autoimmune disease, 
affecting 0.5-1% of the population, with a female to male ratio of 3:1. The disease is 
characterized by synovial inflammation, so called synovitis, and the subsequent formation of 
the pannus, a thick cellular layer on the joint surface. The leukocyte infiltrate includes 
granulocytes, monocytes/macrophages, B cells, T cells  (CD4+ and CD8+)), mast cells, and 
NK cells, which produce large amounts of proinflammatory cytokines, chemokines, and 
degrading enzymes [1, 2].  
Chronic joint inflammation causes cartilage and bone destruction, dysfunction of diarthrodial 
joints, pain and disability. Joint pain is one of the dominant symptoms of RA and often 
develops before joint inflammation and clinical symptoms of arthritis [3]. During disease 
progression, other organs may also become affected, and as a consequence, systemic 
cardiovascular, pulmonary, and skeletal complications frequently present [2]. 
1.1.1 Classification criteria of RA 
Until 2010, the American College of Rheumatology (ACR) 1987 revised classification 
criteria of RA [4] were used for diagnosing patients, and in clinical trials and for treatment 
recommendations. However, this set of criteria has been criticized for the lack of sensitivity 
in early disease. Hence, to overcome this limitation, the ACR and the European League 
Against Rheumatism (EULAR) created and published new classification criteria, aimed at 
achieving earlier diagnosis and treatment (Table 1) [5]. 
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Table 1. The 2010 ACR/EULAR classification criteria for RA 
Criteria Points 
Joint involvement 
Large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
More than 10 joints (at least one small joint) 4 
Serology  (at least one test result is required) 
RF negative and CCP negative 0 
Low titer of RF and low titer of anti-CCP 2 
High titer of RF and high titer of anti-CCP 3 
Acute-phase reactants (at least one test result is required) 
Normal CRP and normal ESR 0 
Abnormal CRP and abnormal ESR 1 
Duration of symptoms 
Less than 6 weeks  0 
6 (or more) weeks 1 
Requirement for using the criteria: Patient should have at least one swollen joint (synovitis) 
that is not better explained by another disease.  
To classify for rheumatoid arthritis: Add all the applicable points from each subgroup.         
A score of 6 (or more) is required for classification as definite RA.  
Table adapted from Aletaha et al. 2010 Rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9): 2569-
2581. 
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1.2 AUTOANTIBODIES IN RA  
Rheumatoid arthritis is known as an autoimmune disease due to the presence of 
autoantibodies. The most frequent and the most studied RA-related autoantibodies are the 
rheumatoid factor (RF) and the anti-citrullinated protein antibodies (ACPA). More recently, 
a variety of anti-modified protein antibodies (AMPA) have been described in RA, and there 
is data showing that more than 50% of patients have a spectrum of AMPAs directed 
against post-translational modifications (PTMs), including citrullination, acetylation, and 
carbamylation [6]. 
1.2.1 Rheumatoid factor 
Historically, rheumatoid factor (RF) was described as the main serological marker in RA, 
and it was the only serological marker included in the 1987 revised classification criteria 
[5]. Rheumatoid factor is an antibody (mainly IgM, but also IgG and IgA are present) 
reactive with the Fc portion of IgG. Although RF is detected in approximately 70% of RA 
patients, the presence of RF is not specific for RA as these autoantibodies are also present 
in a variety of other diseases and in 5% of the general population. Some studies suggest a 
synergistic role for RF and ACPA in initiating RA-associated inflammation.  The presence 
of both IgM RF and ACPA IgG was shown to associate with significantly increased 
disease activity score for 28 joints (DAS28) as well as with increased levels of 
inflammatory markers, suggesting that interaction between IgM RF and ACPA IgG may 
directly contribute to the pathogenesis of RA [7]. 
1.2.2 ACPA 
Anti-citrullinated protein antibodies are the most disease-specific autoantibodies in RA, 
with a specificity of around 98% and a sensitivity of 60-70% [6, 8-10]. ACPA can be 
detected more than 10 years prior to RA manifestations and are strongly associated with 
genetic and environmental risk factors for RA [11, 12]. The presence of these 
autoantibodies also predicts a more severe, erosive and destructive disease process, 
suggesting a pathogenic involvement [13]. Moreover, recent studies show that ACPAs can 
induce osteoclast activation and bone resorption in vitro and in experimental animal 
models, and that this effect is mediated by IL-8 [14, 15].  
There is also experimental evidence suggesting that ACPAs can induce joint pain. Mice 
injected with either human or murinized ACPAs developed pain-like behavior; ACPAs 
bound osteoclasts in the bone marrow and induced CXCL1/2 expression in the joints. 
CXCL1 is a nociceptive chemokine, an analog to human IL-8, which activates nociceptive 
nerve signaling and pain [16]. 
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1.3 PROTEIN CITRULLINATION   
Citrullination, also known as deimination, is the post-translational conversion of positively 
charged peptidylarginine to neutral peptidylcitrulline. This is an enzymatic process driven 
by a family of calcium-dependent peptidyl arginine deiminases (PADs), (Figure 1) [17]. 
Citrullination can affect the three-dimensional structure of a protein and its solubility, 
which is crucial in generating new structural proteins, but in the context of RA it could also 
result in the generation of neo-epitopes, and the subsequent breach of immunological 
tolerance.   
 
 
Figure 1 Schematic illustration of the peptidyl-arginine deamination process by PAD. Figure from van 
Boekel et al, Arthritis Res. 2002;4(2):87-93. 
 
Citrullination has an important role in physiological processes and occurs naturally: I) in 
the skin, citrullination plays a role in keratinization and cornification, by deimination of 
pro-filagrin and keratin; II) in the central nervous system (CNS), citrullination is important 
for plasticity and insulation of neuronal axons, by citrullination of myelin basic protein; 
and III) through chromatin remodeling, citrullination participates in gene regulation. 
Deimination is also part of the innate immune system’s response to bacterial infection, 
through hypercitrullination of histones, which is important for the generation of neutrophil 
extracellular traps (NETs) during NETosis. In addition, increased protein citrullination has 
been linked to chronic inflammation in various tissues. So, citrullination is not restricted to 
RA, and it has been suggested to play a pathogenic role in several diseases, including 
multiple sclerosis, Alzheimer’s disease, psoriasis, glaucoma, neuropathy, and                
myositis [18].  
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1.3.1 PAD enzymes 
Protein citrullination is catalysed by PAD enzymes, and since PAD enzymes require high 
concentrations of Ca2+, deimination is more likely to occur in association with cell death 
(e.g. apoptosis, necrosis and terminal differentiation of cells), when the membrane integrity 
is lost resulting in Ca2+ influx, and in condition such as chemokine receptor ligation, when 
there is mobilization of free intracellular calcium [17, 19]. 
Five PAD enzymes (PAD1, 2, 3, 4 and 6) have been characterized in humans. All of them 
are encoded by a single gene cluster on chromosome 1p35-36, but each PAD isotype has a 
different tissue distribution [20]. PAD1 and PAD3 are mainly expressed in the epidermis 
and in hair follicles, and are primarily cytoplasmic enzymes. PAD1 citrullinates keratin K1 
while PAD3 targets filaggrin and the structural protein of the hair follicles, trichohylagrin 
[21]. PAD2 is detected in multiple tissues including skeletal muscle, secretory glands, 
brain, and hematopoietic cells [22]. PAD2 is primarily known as a cytoplasmic protein, but 
has also been detected in the nucleus. Vimentin in skeletal muscles and macrophages, 
myelin basic protein in the CNS, as well as α- and β-actins, are all recognized as PAD2 
substrates.  Moreover, histones H3 and H4 can also be citrullinated by nuclear PAD2, 
suggesting a role for PAD2 in gene regulation. PAD4 is expressed mainly in hematopoietic 
cells under normal physiological conditions. However, overexpression of PAD4 was found 
in a wide range of tumors implying that PAD4 plays a role in tumorigenesis [23, 24]. 
PAD4 resides mainly within the nucleus and is the only PAD enzyme with a nuclear 
localization signal sequence. PAD4 plays a crucial role in nuclear function by targeting 
nuclear proteins including histones H2A, H3 and H4, ING4, p300/CBP, and     
nucleoplasmin [25, 26]. PAD6 in humans is mainly restricted to ovary, testis and white 
blood cells, and regulates oocyte cytoskeletal sheet formation and female fertility. Due to 
the loss of the conserved Ca2+ binding residues, it has been suggested that PAD6 is not an 
active enzyme [27, 28]. 
In the context of RA pathogenesis, PAD2 and PAD4 have been recognized as key players. 
Both enzymes are found within the inflamed rheumatoid joint, in synovial fluid as well as 
in the synovial membrane [22, 29, 30]. Since the concentration of Ca2+ in the extracellular 
space is at millimolar levels, PAD released from dying cells during apoptosis, necrosis or 
NETosis could become activated and citrullinate extracellular joint proteins [31]. This 
makes PAD2, and PAD4, the strongest candidates for generating the citrullinated antigens, 
which are targeted by the ACPA response.  Furthermore, several reports have 
demonstrated that PAD4 itself is a target of autoantibodies (anti-PAD4) in a subgroup of 
RA patients, and that anti-PAD4 autoantibodies associate with erosive RA [32, 33], 
suggesting that anti-PAD4 autoantibodies may be useful as a severity biomarker in RA.  It 
has also been shown that RA patients remain positive for anti-PAD4 antibodies over time 
and that some patients seroconvert from anti-PAD4 negative to anti-PAD4 positive during 
disease progression. Anti-PAD4 antibodies did not affect the enzymatic activity of PAD4 
when the small substrate N-α-benzoyl-L-arginine ethyl ester was used. However, this 
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finding may not exclude an in vivo effect on protein citrullination in RA. Human genetic 
studies also support the involvement of PAD4 in RA [34].  
Taken together, these findings support the idea to use PAD enzymes as novel targets for 
drug development. Indeed, it has been shown that in the context of tumorigenesis, 
inhibition of PAD4 by small molecules can turn on the expression of the tumor suppressor 
genes in cancer cells [20]. It has also been demonstrated that PAD4 inhibition alone is 
sufficient to block the development of murine arthritis [35], and in a PAD2 knockout 
model, arthritis was ameliorated [36], suggesting that PAD inhibitors might be a promising 
strategy in future RA therapy.  
1.3.2 Citrullinated autoantigens in RA 
Despite the fact that citrullination is not restricted to RA, the formation of autoantibodies to 
citrullinated proteins, is highly specific for RA. The main clinical test used today for the 
detection of ACPA is the CCP2 ELISA assay, which is based on synthetic cyclic 
citrullinated peptides. These peptides are patent-protected, and were originally identified 
from a phage display library, after screening hundreds of peptides for reactivity with RA sera 
and healthy control sera. The peptides with the highest sensitivity, combined with the highest 
specificity, were selected and included in the CCP2 test [37]. Importantly, the CCP2 peptides 
do not correspond to any known human protein sequence; hence give no information with 
regard to the driving autoantigen(s) in RA. A lot of effort has therefore been put into the 
identification of the "true" in vivo targets of the ACPA response, and a number of candidate 
antigens have been put forward, including fibrinogen, vimentin, α-enolase, collagen type II 
(CII), and more recently histones [38-41]. 
Alpha-enolase 
Alpha-enolase is a glycolytic enzyme expressed as a homo-dimer in most tissues. It is a 
multifunctional protein primarily present in the cytosol, although it is also found in the 
nucleus where it functions as a tumor suppressor, and on the cell surface where it serves as 
a plasminogen-binding receptor, which is upregulated during inflammation. Alpha-enolase 
can bind plasminogen not only on the surface of eukaryotic cells but also on the cell surface 
of bacteria, fungi and parasites [42-44]. Citrullinated α-enolase was first identified as a 
candidate autoantigen in RA after blotting PAD-treated monocytic HL60 cells with RA 
sera, followed by mass spectrometry analysis of the reactive 47kD protein band [45]. 
Approximately 40% of patients with RA have antibodies to the immunodominant epitope 
citrullinated α-enolase peptide-1 (CEP-1), which corresponds to amino acids 5-21 of the 
full-length protein [46]. Alpha-enolase, including the citrullinated form, is abundantly 
expressed in synovial fluid and synovial tissue, in correlation with joint inflammation [47]. 
A bacterial version of enolase exists, with high sequence homology to human α-enolase, 
and anti-CEP-1 antibodies purified from RA sera cross-react with bacterial enolase [46]. 
Based on this observation, it was hypothesized that molecular mimicry could be involved 
in the development of ACPA-positive RA [48].  
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Fibrinogen 
Fibrinogen is a hexameric plasma glycoprotein containing pairs of α, β and γ chains. As a 
precursor of fibrin, fibrinogen plays a central role in coagulation. Deposition of fibrin in the 
rheumatoid joints is found in patients with early arthritis, and there is evidence suggesting 
that this deposition may trigger pannus formation [49]. Fibrinogen, including the 
citrullinated form, is highly expressed in inflamed synovia and synovial fluid of patient with 
RA, and citrullinated fibrinogen (Cit-fib) is one of the most recognized autoantigens in RA, 
with anti-Cit-fib antibodies detected in approximately 50-60% of patients [50, 51]. Studies 
have shown that ACPA - Cit-fib immune complexes can activate macrophage cytokine 
production by binding to Fcγ receptor IIa and TLR4 [7, 52, 53].  
Vimentin 
Vimentin is an intermediate filament protein abundantly expressed in the cytoskeleton of 
eukaryotic cells. Vimentin plays an essential role in organelle transport, cell migration, and 
proliferation. Cell-surface expression and secretion of vimentin from macrophages have 
been shown to be enhanced in response to bacterial infection, and some bacteria use 
extracellular vimentin as an attachment receptor [54]. Citrullinated vimentin (Cit-vim) is 
present in the inflamed joint and antibodies to a mutated citrullinated form of vimentin  
(MCV) are found in approximately 65% of RA patients [55]. Based on these findings, a 
commercial ELISA test, the MCV assay, was developed, with similar sensitivity and 
specificity as the CCP2 ELISA [56]. Anti-Cit-vim antibodies have been shown to induce 
osteoclastogenesis and to play a role in apoptosis and inflammation [14].  
Collagen type II 
Collagen type II (CII) is a major component of articular cartilage, and immunization with 
CII cause arthritis in mice and rats [57], making CII an attractive autoantigen in RA. 
Antibodies to the native form of CII can be detected in 15-25% of RA patients. However, 
these antibodies are also found in other inflammatory and autoimmune diseases [58]. 
Citrullination of CII has been shown to enhance arthritis in an experimental rat model [59]. 
Moreover, an immunodominant citrullinated epitope on CII, the Cit-C1 epitope, have been 
described as an antibody target in approximately 40% of RA patients [60], and anti-Cit-C1 
antibodies also mediate arthritis in mice [61]. In addition to Cit-C1, often Cit-CII epitopes 
have been described and affinity purified ACPA against them could bind RA cartilage, 
suggesting that the anti-Cit-CII antibody response contributes to cartilage              
degradation [62]. 
Histones 
Histones are nuclear proteins, which enable package of DNA into tight bundles, and in 
response to posttranslational modifications, such as phosphorylation, acetylation, 
methylation and citrullination, histones can regulate gene transcription. Neutrophils 
infiltrating the joints contribute to inflammation through the release of reactive oxygen 
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species (ROS), as well as the release of NETs during NETosis. Core histones are the most 
abundant proteins in NETs [63], and several reports indicate that hypercitrullinated 
histones in NETs (i.e. H2A, H2B, H3 and H4) are targets of the ACPA response [38, 64]. 
High levels of Cit-H2B and immune complexes containing Cit-H2B have been detected in 
the synovial fluid of RA patients, and Cit-H2B has also been shown to have an 
arthritogenic potential in a mouse model of arthritis [65]. 
 
1.4 GENETIC RISK FACTORS FOR RA  
1.4.1 HLA-DRB1 SE 
The connection between genetic susceptibility and RA has been studied intensively during 
the past 40 years. Since then many breakthroughs have been made. The major 
susceptibility alleles for RA are present in HLA-DR4, -DR1, and -DR10, principally 
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *1001, and *1402. These HLA-DR 
alleles have been described as the “Shared Epitope” (SE), as they encode a similar amino 
acid sequence, the shared epitope sequence, within the peptide-binding groove of the beta 
chain of the HLA-DR molecule [66, 67]. Interestingly, the association between HLA-SE 
and RA is restricted to ACPA-positive RA [11], and it has been shown that the positively 
charged P4 pocket in HLA-DR favors binding of peptides containing neutral citrulline, 
rather than positively charged arginine [8].  Hence, the transformation of arginine to 
citrulline by PAD enzymes could promote HLA-SE binding and antigen presentation to T 
cells, (Figure 2). 
 
 
Figure 2 Schematic illustration of the interaction between the citrullinated peptide-antigen - MHC complex 
on an antigen-presenting cell (APC), and the T cell receptor (TCR) on a naïve T cell. Neutral citrullinated 
peptide residues (red rings) bind the positively charged P4 pocket of HLA-DRB1 SE molecules, or interact 
directly with the TCR. Figure from Malmström et al, Nat Rev Immunol. 2017 Jan;17(1):60-75. 
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1.4.2 PTPN22  polymorphism 
Another genetic risk factor described in RA is the protein tyrosine phosphatase non 
receptor type 22 (PTPN22) 1858C/T polymorphism. PTPN22 encodes the protein 
tyrosine phosphatase LYP that is involved in T- and B-cell signaling.  The presence of the 
risk allele has been shown to influence activation of autoreactive T cells and reduce 
negative selection of B cells. This results in a more autoimmune-prone repertoire of B- 
and T cells [8, 68-70].  Like HLA-SE, the PTPN22 risk allele has been reported to be 
related mainly to ACPA-positive RA, and PTPN22 shows a strong gene-gene interaction 
with HLA-SE in the development of ACPA-positive RA [71].  
1.4.3 Other risk genes 
Genome-wide association studies in several large cohorts describe additional gene loci 
such as TRAF1-C5, STAT4, REL, TNFAIP3, CTLA, and CD40 in RA pathogenesis [72]. 
Most of these have been associated specifically with ACPA-positive disease [40, 73]. 
Another genetic factor associated with ACPA-positive RA is polymorphism of the PADI4 
gene [34]. This association seems to be stronger in Japanese and Korean population, 
compared to Western Europeans.  
 
1.5 ENVIRONMENTAL RISK FACTORS FOR RA 
In addition to genetic susceptibility, environmental factors and life style contribute to the 
development of RA. Smoking, silica- and textile dust, air pollution, viruses and other 
microbial exposures, as well as hormones have all been described as risk factors                  
for RA [40].  
1.5.1 Smoking  
The best-known environmental risk factor for the development of RA is cigarette smoking. 
The association between smoking and RA was first found in 1987 [74], and later  
confirmed in a number of studies, including twin studies [75].  Cigarette smoking 
contributes more to RF-positive [76] and ACPA-positive RA [77]. Moreover, there is a 
strong interaction between smoking and HLA-DRB1 SE alleles in ACPA-positive               
RA [11, 78, 79]. It is well known that cigarette smoke contains a lot of toxic compounds 
that may cause tissue damage and inflammation. Cigarette smoke increases recruitment 
and activation of immune cells in the lungs, and elevated serum levels of matrix 
metalloproteinases, CRP, IL-6, IL-1β, TNF-α, and fibrinogen, as well as increased 
expression of Fas on T and B cells [40]. Nicotine, the most abundant component of 
cigarette smoke, is probably not responsible for the association between cigarette smoking 
and risk of RA. In some studies, nicotine has even been demonstrated to have protective 
effects [77, 80]. Interestingly, increased expression of PAD2 and citrullinated proteins 
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have been described in the lungs of smokers compare to non-smokers [11, 81], and the 
presence anti-CCP IgA, as well as RF IgA, is associated with smoking in RA                 
patients [82, 83].   
1.5.2 Microbial exposure: viruses and bacteria 
An attractive hypothesis for the development of RA, as well as other autoimmune diseases, 
is that the disease is triggered by an infection. An immune response against pathogens 
could cause tissue destruction and cell death, which could lead to the release and exposure 
of intracellular and/or nuclear proteins to the immune system. In an inflammatory 
environment, and in the presence of danger molecules, this may cause break of immune 
tolerance to self-proteins. Alternatively, an immune response against viral or bacterial 
antigens may target epitopes on human proteins by mechanisms of molecular mimicry. 
Historically, a number of pathogens, both viruses and bacteria, have been linked to RA. 
However, data from different groups have been contradictory.  
Viruses 
The association between infection by viruses and the development of RA has been a long 
lasting discussion. The link between RA and a virus was first described for Epstein-Barr 
virus (EBV).  It was shown that patients with RA compared to controls have increased 
antibody levels against EBV [84, 85]. Later on, the involvement of other viral infections 
such as human parvovirus B19 (B19) [86] and cytomegalovirus (CMV) [87] was described 
in the pathogenesis of RA. However, studies investigating the link between viral infections 
and RA are contradictory. Some serological studies have demonstrated higher antibody 
levels against mentioned viruses in RA compared to controls, while others were not able to 
show the same results [88]. Moreover, some studies reported the detection of viral DNA in 
the synovium and bone marrow of RA patients [89]. However, others studies could not 
confirm these findings [90, 91]. A recent report suggests an association between low anti-
EBV/anti-B19 antibody levels and ACPA-positive RA, in the context of HLA-DRB1 SE, 
suggesting that high anti-viral antibody levels could potentially protect against ACPA-
positive RA [92]. 
Bacteria 
In addition to viruses, there is growing evidence suggesting that bacterial dysbiosis 
contributes to the initiation and progression of RA. Due to the fact that autoantibodies 
precede the onset of clinically classifiable RA, it has been hypothesised that the initial 
inflammation begins outside of the joints, in mucosal tissues such as the lungs, the gut and 
the periodontal regions [3]. Involvement of the lungs in RA etiology and pathogenesis is 
well recognized today [77]. In addition, several animal studies have shown the ability of 
intestinal microbes to trigger arthritis, and RA patients have an altered gut microflora 
compared to controls [93]. Based on the epidemiological link between chronic 
periodontitis and RA, the gum mucosa has also raised interest in this respect [94, 95]. 
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1.6 AETIOLOGY OF PD  
Periodontitis is one of the most common chronic inflammatory diseases in humans, 
affecting approximately 30% of the population worldwide, with 10-15% suffering from the 
most severe form [96]. Chronic PD is a complex, multifactorial disease, characterized by 
the destruction of the tooth-supporting tissue. A microbial shift in the gingiva - towards 
pathogenic microorganism - results in a local inflammation called gingivitis, and if 
untreated gingivitis could progress to chronic periodontitis (PD).  
The surface of the oral cavity harbours around six billion bacteria, which are represented 
by approximately 700 species. The diverse community of oral microbiota includes also 
other types of the microorganisms such as fungi, mycoplasma and protozoa [96].  This 
community, called the “climax community”, is very stable, and a shift of microbiota from 
gram-positive, facultative, fermentative microorganisms to predominantly gram-negative, 
anaerobic, proteolytic organisms triggers pathological changes in the periodontium. The 
consortium of periodontal pathogens detected in periodontal pockets includes: 
Aggregatibacter actinimycetemcomitans (Aa), Porphyromonas. gingivalis (P.gin), 
Tannerella forsythia, Prevotella intermedia, Fusobacterium, Campybacter rectus, 
Eubacterium, Streptococcus intermedia and Treponema denticola; the three most common 
species (P.gin, T.forsythia and T. denticola) form the so-called “red complex”.  
The induction and progression of PD begins with a plaque accumulation initiated by early 
colonizers, followed by late colonizers, i.e. the red complex pathogens, and release of 
bacterial substances, which cause an inflammatory response. Over time, the bacteria in the 
periodontal pocket become resistance to attack by neutrophils and phagocytes, ROS, 
bactericidal proteins and peptides, and this ultimately leads to the development of chronic 
inflammation [97, 98]. In other words, tissue damage of the periodontium results from a 
dysregulated innate immune response against the bacteria rather than by the bacteria 
themselves. 
1.6.1 Porphyromonas gingivalis 
Porphyromonas gingivalis is recognized as a keystone pathogen involved in the 
pathogenesis and progression of PD. This bacterium was found in more than 85% of 
samples from patients with chronic PD, and there are a number of studies showing that 
serum levels of antibodies against P.gin are higher in patients with PD, compared to 
periodontally healthy controls. P. gingivalis serves as a secondary colonizer of dental 
plaque and often adhere to the primary colonizers, including P. intermedia. It can be 
divided into invasive and non-invasive strains, and both in vivo and in vitro data show that 
the invasive form of P.gin is more pathogenic than the non-invasive [99]. 
P. gingivalis produces a broad array of virulence factors, including: lipopolysaccharide 
(LPS), lipoteichoic acids, haemagglutinins, gingipains, outer membrane proteins and 
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vesicles. Some of these virulence factors, and the associated effects, are listed in Table 2.  
P. gingivalis uses these factors to overcome the host external protective barriers, colonize 
the subgingival plaque, and modulate the host immune response. 
Table 2. Virulence factors of P.gin and their effects 
Virulence factor Effects 
Enzymes (e.g. hyaluronidase, chondroitin 
sulfatase, capsule) 
Decrease phagocytosis,  
Inhibition of chemotaxis 
Lipopolysaccharide (LPS) Bone resorption 
Immunoglobulin proteases 
Fimbriae, exopolysaccharide, outer 
membrane proteins 
Adhesion or attachment to host cell outer 
membrane 
Collagenase, trypsin-like protease Degradation of plasma protease inhibitors 
Destruction of periodontal tissue 
Gingipains Uncontrolled proteolysis  
Activation of the kallikrein/kinin pathway   
Development of edema 
Activation of the complement system  
Degradation of fibrin 
P.PAD Citrullination of proteins/ peptides (e.g. 
bradikinin, anaphylotoxin C5a, and 
epidermal growth factor) 
Aminopeptidase Degradation of iron transport protein 
 
Table adapted from How et al: Porphyromonas gingivalis: An Overview of Periodontopathic Pathogen below 
the Gum Line. Front Microbiol 2016, 7:53 
 
P.gin LPS 
Lipopolysaccharide is key factor in the development of PD, and detected in over 50% of 
patients suffering from chronic PD. P.gin LPS triggers release of pro-inflammatory 
cytokines such as IL-1β, IL-6 and IL8, and matrix metalloproteinase, which cause tissue 
destruction. Moreover, P.gin LPS inhibits alkaline phosphatase activity and production of 
collagen type I, and stimulates the expression of adhesion molecules in a dose dependent 
manner. These mechanisms help P.gin colonize the subgingival plaque, and to evade the 
immune system [96]. 
P.gin gingipains  
Arginine- and lysine-specific cysteine proteases, called gingipains, are recognized as the 
main virulence factors of P.gin. They are expressed in cell-associated- as well as secretory 
forms, and they cleave peptides after arginine- (R-gingipains) or lysine residues (K-
gingipains). The action of gingipains results in uncontrolled proteolysis and 
kallikrein/kinin pathway activation, which leads to the development of edema. 
Furthermore, R-gingipain activates complement and neutrophil infiltration, and                    
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K-gingipain contributes to increased bleeding by degradation of fibrin. Moreover, 
degradation of antimicrobial peptides by gingipains helps other bacteria to co-aggregate 
with P.gin and thereby to persist in the gingival tissue. Gingipains also cleave and activate 
the proteinase-activated receptor-2 (PAR-2) on neutrophils, which helps to maintain a pro-
inflammatory-signaling pathway [96, 100].  
P.gin PAD enzyme 
P. gingivalis is the only known microorganism to express a PAD enzyme (P.PAD). The 
P.PAD gene is not related to the human PADI genes, and P.PAD has different properties 
compared to human PADs. First of all, P.PAD does not require Ca2+ for activity, but needs 
a higher pH than human PADs for optimal function. Moreover, P.PAD, unlike human 
PADs, deiminates C-terminal arginine residues, and is also able to citrullinate free 
arginine[101].  
Importantly, there is no citrullination detected in arginine-gingipan-null mutants of P.gin, 
meaning that citrullination depends on the activity of R-gingipains [102, 103]. Indeed, R-
gingipains co-localize with P.PAD on the bacterial outer membrane or in secreted vesicles, 
and cleave host proteins/peptides after arginine, exposing C-terminal arginine, which is 
subsequently citrullinated by P.PAD [101]. P.PAD participates in inflammation and 
homeostasis in the infected periodontium by citrullinating bradikinin, anaphylotoxin C5a, 
and epidermal growth factor. There is also data suggesting that P.PAD plays a role in 
prostaglandin secretion from infected fibroblasts [104].  
The generation of citrullinated host peptides and protein fragments by the combined 
actions of P.PAD and R-gingipains may lead to the exposure of endogenous neo-epitopes 
to the immune system, and there is data demonstrating that P.PAD can citrullinate both α-
enolase and fibrinogen, two of the main candidate autoantigens in RA [103]. In addition to 
citrullination of host proteins, there is emerging evidence suggesting that P.PAD is capable 
of autocitrullination; analysis by mass spectrometry, reveled citrullination of 7 out of 18 
arginines in the P.PAD polypeptide chain. Interestingly, all of them were internal 
arginines/citrullines [105]. A recent analysis of the P.gin “citrullinome” showed that up to 
25 P.gin proteins were potentially citrullinated [106]. The same study also showed that the 
ability to generate citrullinated proteins was dependent on the P.gin strain, as only one out 
of two commonly used lab strains, and one out of three clinical isolates, could produce 
citrullinated peptides.  
 
1.7 THE LINK BETWEEN PD AND RA  
Both RA and PD are chronic inflammatory diseases ultimately resulting in soft tissue 
destruction and progressive bone erosion.  The link between these two diseases could be 
non-causal, and depend on common genetic and environmental risk factors such as 
smoking and lifestyle, including stress, nutrition and socioeconomic status. Among the 
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genetic risk factors, expression of HLA-DRB1 SE subtypes (0401, 0404, 0405, 0408) have 
been associated to both ACPA positive RA and progressive severe periodontitis [98]. A 
causal link on the other hand, where PD drives RA, was first proposed by Rosenstein et al 
[107], and involves citrullination of bacterial and human proteins by P.PAD, followed by 
break of immune tolerance and production of ACPA in genetically predisposed individuals 
[48, 98]. This hypothesis is supported by the fact that the autoimmune response in RA - in 
the form of ACPA - often precede clinical joint symptoms by several years [12], 
suggesting that RA is precipitated outside the joints, potentially in the gum mucosa, where 
citrullinated proteins are exposed to the immune system in an inflammatory environment 
[108]. In addition to P.PAD, human PAD2 and PAD4 are expressed and active in the 
gingiva during chronic periodontitis [109], and another oral pathogen, Aa, has been 
suggested to play a role in the generation of citrullinated proteins in the oral cavity by 
inducing hypercitrullination in neutrophils and thereby generate multiple RA        
autoantigens [110]. 
1.7.1 Epidemiological evidence  
Many well-designed studies show that PD is more prevalent in patients with RA compared 
to non-RA controls, and vice versa. In one study for example, RA patients were found to 
be more often edentulous and suffer from PD, compared to non-RA controls [111]. In 
another study, the largest population-based case-control study performed to date (13 779 
RA cases and 137 790 controls), an association was identified between PD and incident 
cases of newly diagnosed RA [94]. It should be mentioned though, that a number of other 
studies have not been able to find a significant association between PD and RA, including 
the largest prospective register-based study conducted so far (81 132 participants including 
292 incident RA cases), where a history of periodontal surgery and/or tooth loss was 
investigated in relation to risk of RA [112]. Also a recent study, where the Epidemiological 
Investigation of RA (EIRA) cohort was linked to the Swedish Dental Health Register, 
failed to find an association between RA and PD [113]. Still, a meta-analysis recently 
confirmed that there is strong evidence for an epidemiological association between PD and 
RA [95]. 
In addition, another recent meta-analysis demonstrated significantly higher anti-P.gin 
antibody levels in RA, compared to healthy controls [114], and a positive correlation 
between anti-P.gin antibody levels and ACPA has been shown [115]. Moreover, elevated 
anti-P.gin antibody levels have been detected in individuals at increased risk of developing 
RA [116, 117]. Thus, the epidemiological association between PD and RA seems to be 
present even before clinical onset of arthritis [118]. 
1.7.2 Evidence from animal studies  
The majority of animal studies of RA and/or PD describe aggravated clinical symptoms of 
arthritis in mice and rats after being infected with P.gin. A number of studies have shown 
massive influx of leukocytes, accumulation of osteoclasts as well as cartilage and bone 
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erosion in joints after P.gin infection [98, 119]. Moreover, the inflammatory reaction in 
infected mice went beyond the joint and oral cavity and resulted in a systemic Th17 
response [98, 119]. Another study confirmed the role of IL-17 in linking experimental PD 
and arthritis. In this study, mice with adjuvant-induced arthritis and P.gin infection had 
more severe joint damage, elevated number of Th17 cells and neutrophils, as well as 
increased TNF and IL-17 levels, compared to non-infected mice [120]. In another 
experimental study, ACPAs were found in animals infected with wild type P.gin but not in 
mice infected with the P.PAD-null strain [121].  
 
1.8 AN AETIOLOGICAL HYPOTESIS LINKING P.GIN TO ACPA-POSITIVE RA  
Mucosal surfaces, such as gums and lungs, may be exposed to environmental agents like 
smoking and microorganisms, including P.gin and Aa, which could trigger innate immune 
reactions and local inflammation. In this setting, human and bacterial PAD enzymes could 
become activated, which leads to increased protein citrullination, including 
autocitrullination of P.PAD, and the generation of neo-epitopes (Figure 3.1). In the 
presence of “danger signals” (e.g. toxic components from the smoke, bacterial DNA and 
LPS), B cells may become activated and start to produce anti-P.gin antibodies as well as 
low titers of low-affinity ACPAs, which can be detect in the circulation years before 
clinical symptoms of RA develops (Figure 3.2). In individuals carrying risk alleles such as 
the HLA-DRB1 SE and PTPN22 polymorphism, autoreactive T cells - that have escaped 
negative selection - could be activated by B cells presenting citrullinated peptides, derived 
from endogenous proteins, on MHC class II (i.e. SE) (Figure 3.3). As a consequence, 
activated autoreactive T cells stimulate the citrulline-specific B cells to produce high titers 
of high-affinity ACPAs. Through epitope-spreading and/or cross-reactivity, these ACPAs 
may later target citrullinated joint proteins, for example on osteoclasts, form immune 
complexes and ultimately cause chronic joint inflammation (Figure 3.4). 
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Figure 3 Schematic illustration of the etiological hypothesis linking P.gingivalis to the development of 
ACPA-positive RA. 
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2 AIMS OF THE THESIS  
 
The overall aim of this PhD project was to investigate whether the oral pathogen 
Porphyromonas gingivalis is etiologically linked to the development of RA, specifically 
ACPA-positive RA. Specific aims included:  
1. To investigated the fine-specificity of the ACPA response in relation to well-known RA 
risk factors (i.e. HLA-DRB1 SE, PTPN22 polymorphism and cigarette smoking) (Study I) 
2. To characterise the subset of RA patients with a heightened immune response to          
P.gin R-gingipain, in terms of genetic risk factors, smoking and the ACPA                 
response (Study II) 
3. To analyse the antibody response to P.gin in blood samples collected before the onset of 
clinical RA, in relation to the ACPA response (Study III) 
4. To characterize the antibody response to a citrullinated peptide derived from P.PAD in 
RA, in relation to genetic risk factors, smoking, disease activity, and the ACPA response 
(Study IV)
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3 MATERIAL AND METHODS 
3.1 PATIENT MATERIAL  
All four studies included in this PhD thesis are based on human material, from patients with 
RA or PD and healthy controls. In Study I, II and IV, the serum biobank from the 
population-based RA case-control study EIRA (Epidemiological Investigation of RA) was 
used, and in Study III, serum samples from the population-based Biobank of the Northern 
Sweden Health and Disease Study (NSHDS) cohort as well as the Maternity cohort was 
used. In addition, a small serum cohort of patients with PD and periodontally healthy controls 
was used in Study II and IV, and monoclonal antibodies derived from RA blood, -synovial 
tissue and -synovial fluid was used in Study IV. All samples and information related to the 
study subjects were collected with informed consent and ethical approval in compliance 
with the Declaration of Helsinki [122].  
3.1.1 EIRA   
In Study I, II and III we analysed antibody reactivities in serum samples from the EIRA 
cohort. This population-based case-control study was initiated in May 1996 and is ongoing. 
Incident cases of RA (aged 18-70 years), diagnosed in accordance with the 1987 revised 
ACR criteria, were recruited within 12 months after the first symptoms of arthritis from the 
southern and middle parts of Sweden. Controls were randomly selected from the national 
population register, and matched on age, gender and residential area [76]. All EIRA 
participants donated blood at the time of inclusion and filled in an extensive questionnaire 
relating to life style and environmental exposures, including detailed smoking history. 
Serum samples were frozen (stored at minus 80°C) for future serological analyses; 
genotyping was performed on DNA from whole blood, for HLA-DRB1 shared SE alleles 
(Olerup SSP kit) and PTPN22 (rs2476601) polymorphism (TaqMan allelic discrimination 
PCR) [71]. Patients in EIRA are also registered in the nationwide Swedish Rheumatology 
Register, from where data on disease activity score for 28 joints (DAS28) and C-reactive 
protein (CRP) levels (mg/l) were collected for Study IV [123].  
3.1.2 A case-control study within NSHDS and the Maternity cohort  
In Study III, antibody reactivities were analysed in plasma/serum samples collected before 
the onset of clinical RA. This was done as a case-control study within the population-based 
Biobank of the Northern Sweden Health and Disease Study (NSHDS) cohort and the 
Maternity cohort of Northern Sweden. The study design has been described previously [12]. 
Briefly, the NSHDS cohort is based on health surveys, where all habitants of Västerbotten 
County are continuously invited to participate. Study subjects donate blood and complete a 
self-administered questionnaire for the collection of demographic, medical, and lifestyle 
information, including smoking status and diet. The Maternity cohort is based on blood 
samples collected from pregnant women that have been screened for immunity to rubella. 
In order to identify individuals in these cohorts who have donated blood before the onset of 
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symptoms of RA, a register linkage was performed using the register of patients with RA 
(fulfilling the ARA 1987 classification criteria for RA) at the Department of Rheumatology, 
University Hospital, Umeå established since 1995. A total of 251 RA patients were 
identified who had donated at least one blood sample before having symptoms of the 
subsequent RA disease. These individuals had together donated 422 plasma/serum samples 
at various time points before the onset of symptoms of RA (375 from the Biobank cohorts 
and 47 from the Maternity cohort): the majority had only donated one blood sample; 92 
individuals (36.6%) had donated two samples; 46 individuals (18.3%) had donated three 
samples; 22 individuals (8.8%) had donated four samples; nine individuals (3.6%) had 
donated five samples; and two individuals (0.8%) had donated six samples. A blood sample 
taken at the time of RA diagnosis (≤12 months of symptoms) was available for 192 of these 
251 individuals. Controls (n=198) were selected from the same cohorts as the pre-
symptomatic individuals and matched for age and gender. Serum/plasma samples were 
stored frozen for future serological analyses; genotyping for HLA-DRB1 SE alleles and 
PTPN22 (1858C/T) polymorphism were performed as described [124]. 
3.1.3 PD- and non-PD cohort  
In addition to the larger population-based cohorts described above, serum samples from 
patients with chronic PD (n=66) and gender-matched periodontally healthy controls (n=63) 
were screened for antibody reactivities in Study II and IV. All study subjects were examined 
by dentists at the Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden. 
Clinical criteria for PD were: bone resorption with attachment loss ≥5mm, pocket probing 
depth ≥4mm, and bleeding on probing. Periodontally healthy controls had no signs of 
gingival inflammation, clinical attachment level ≤3.5 mm, pocket probing depth ≤3.0 mm, 
and no bleeding on probing.  
 
3.2 ELISA    
The main method used in the studies included in this PhD thesis is the ELISA assay. For 
detection of anti-CCP2 IgG (Study I-IV), the commercially available Immunoscan 
CCPlus® kit was used (Euro-Diagnostica AB, Malmö, Sweden), according to the 
manufacturer’s instructions with a cut-off for positivity set at ≥25 AU/ml. Information on 
RF status (positive or negative) in Study II had been collected from patient journals, and 
was in most cases assayed by nephelometry, while analysis of RF in Study III, was 
performed using the EliA assay on the Phadia 2500-system was used (Phadia GmbH, 
Freiburg, Germany), in accordance with the manufacturer’s instructions. For detection of 
antibodies against bacterial antigens and ACPA fine-specificities (Studies 1-IV), in-house 
protein- and peptide ELISAs were used (descriptions of these antigens are presented in 
Table 3).  
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Table 3 Coating antigens used in the in-house ELISAs 
Antigen  Peptide sequence Origin 
RgpB 
 Full length protein 
Arginine gingipain B,  
purified from P.gin 
CPP3  
 C-AKTDSYWT-CIT-DYTGWFAMYD-C 
P.gin PAD,  
amino acids:  121-139 
CEP-1  
 C-KIHA-CIT-EIFDS-CIT-GNPTVE-C 
Human α-enolase,  
amino acids: 5-21 
Cit-Vim60-75  
 VYAT-CIT-SSAV-CIT-L-CIT-SSVP 
Human vimentin,  
amino acids: 60-75 
Cit-Fib36-52  
 NEEGFFSA-CIT-GHRPLDKK 
Human fibrinogen β-chain,  
amino acids: 36-52 
Cit-C1  
 (GPP*)5-GA-CIT-GLTG-CIT-P*-GDA-(GPP*)2-GKKYG 
Human CII, C1 epitope,  
amino acids: 355-378 
CIT = citrulline; P* = hydroxyproline  
 
3.2.1 ACPA fine-specificity ELISA  
In Study I, we measured antibodies against four synthetic citrullinated peptides, described as 
candidate autoantigens in RA: CEP-1, Cit-vim60-75, Cit-fib36-52, and Cit-C1, corresponding to 
epitopes on citrullinated α-enolase, vimentin, fibrinogen and CII (Table 3). Reactivity against 
the corresponding arginine-containing control peptides was analysed in parallel. In brief, 96-
well plates were coated with peptide antigens diluted in 50mM carbonate buffer: CEP-
1/REP-1 (5µg/ml) and Cit-C1/Arg-C1 (10µg/ml) were coated on MaxiSorp (Nunc) plates at 
4°C over night; biotinylated Cit-vim60-75/Arg-vim60-75 and Cit-fib36-52/Arg-fib36-52 (1µg/ml) 
were coated on streptavidine (Pierce, Thermo Scientific) plates at room temperature (RT) 
for 1h (note, streptavidine plates were washed in PBS, 0.5% Tween, prior addition of 
antigen). Following antigen incubation, plates were washed (PBS, 0.5% Tween) and CEP-
1/Cit-C1 plates were also blocked (PBS, 1% BSA) for 1h at RT, before adding serum 
samples, diluted 1:100 in RIA buffer (10mM Tris, 1% BSA, 350mM NaCl, 1% Triton-X, 
0.5% sodium deoxycholate, 0.1% SDS). The serum samples were subsequently incubated 
for 1h at RT, before plates were washed again (PBS, 0.5% Tween) and incubated for 1h in 
RT with horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Jacksson), diluted 
1:10,000 in RIA buffer. After a final wash, TMB substrate (Sigma) was added, and the 
colour reaction stopped by addition of 1M H2SO4. Absorbance was measured at 450nm, 
and optical density (OD) was expressed as arbitrary units (AU/ml) for the ACPA responses, 
based on standard curves. The standard curves were derived from antibody-positive serum 
pools added to the plates in serial dilutions.  Serum samples were analysed in duplicates, 
and blank wells (only RIA buffer), as well as positive and negative control serum, were 
included on all plates. Cut-off values for positivity were based on the 98th percentile among 
150 EIRA controls. For comparison of ACPA fine-specificity responses, each cut-off value 
was converted to 10AU/ml.  
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 3.2.2 CPP3/RPP3 IgG ELISA 
In Study III and in Study IV, we analysed reactivity against the citrullinated P.PAD-derived 
peptide CPP3 and the arginine-containing control version RPP3. The same protocol as 
described above was used, with some modifications: Coating concentration for CPP3 and 
RPP3 was 10µg/ml. In Study III, cut-off for CPP3-positivity was calculated using receiver 
operating characteristic (ROC) curves, based on reactivity among 192 RA cases and 198 
population-based controls from the NSHDS and the Maternity cohorts, giving a specificity 
of 96%. In Study IV, a cut-off based on the 100th percentile among 63 periodontally 
healthy controls was used when analyzing the anti-CPP3 antibody response in patients with 
chronic PD. In addition, 218 human monoclonal antibodies were screened at 10µg/ml for 
CPP3/RPP3 reactivity using the CPP3/RPP3 ELISA; positive clones were re-analysed in 
serial dilution (1:2 steps, starting at 20µg/ml), and unspecific binding was evaluated by 
including uncoated wells (i.e. 2% BSA). 
3.2.3 RgpB IgG ELISA 
In Study II and Study III we used a protein-based ELISA to analyse the presence of 
antibodies against R-gingipain B (RgpB). The coating antigen, C-terminal hexahistidine-
tagged RgpB protein, was purified from the growth medium of genetically modified P.gin 
strain W83, by affinity chromatography on Ni-Sepharose, as previously described [125]. 
The same protocol as outlined above was used, with some modifications: Coating 
concentration was 2.5µg/ml, and serum was diluted 1:800. In Study II, cut-off for positivity 
was set at the 95th percentile, based on reactivity among 59 periodontally healthy controls, 
while in Study III, no specific cut-off was set for the anti-RgpB antibody response. Anti-
RgpB IgG levels were presented as arbitrary units (AU/ml), based on a standard curve made 
from a serially diluted highly positive serum pool. 
 
3.3 PEPTIDE ABSORPTION ASSAY  
In Study I, cross-reactivity between different ACPA fine-specificities (CEP-1, Cit-vim60-75, 
Cit-fib36-52, and Cit-C1) was examined by peptide absorption experiments. Briefly, serum 
samples with high anti-CCP IgG levels (>800 AU/ml) and multiple ACPA reactivities were 
diluted 1:100 in RIA buffer and incubated with each of the four peptides (CEP-1, Cit-vim, 
Cit-fib or Cit-C1) at 10 μg/ml, or in the presence of buffer alone, for 2h hours at RT, during 
constant agitation. Afterwards, samples were centrifuged at 1000g for 15 minutes, and 
supernatants transferred to peptide-coated ELISA plates, and assayed as described above. 
Evaluation of cross-reactivity was made by comparing ACPA responses in peptide pre-
absorbed serum samples and serum samples incubated without any peptide.  
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3.4 MULTIPLEX PEPTIDE MICROARRAY  
In Study IV, we used a custom-made multiplex peptide microarray, based on the 
ImmunoCAP® ISAC system (Phadia AB, Uppsala, Sweden), for the detection of antibody 
responses, in addition to the ELISA method. This assay allows the simultaneous detection of 
multiple antibody reactivities by high-throughput screening of large numbers of serum 
samples [126]. In brief, glass slides were spotted with peptide antigens before incubated with 
serum (or monoclonal antibodies). Unbound antibodies were then removed by washing, and 
bound antibodies detected using Cy3-conjugated goat anti-human IgG (Jackson 
ImmunoResearch Laboratories, Newmarket, UK) and visualized by laser scanner. 
Fluorescence intensity was converted to normalized arbitrary units, by comparison to 
calibrator samples on each assay run. Cut-off values for each antibody response were set at 
the 98th percentile among 370 EIRA controls. Peptide antigens printed on the glass slides 
included: CPP3 and RPP3, as well as eight citrullinated peptides (and the arginine-containing 
equivalents) derived from human proteins: filaggrin (cfc1-cyc), fibrinogen (Cit-fibα563-583, 
Cit-fibα580-600, Cit-fibß36-52), vimentin (Cit-vim2-17 and Cit-vim60-75), α-enolase (CEP-1) and 
collagen type II (Cit-C1).  
Study III also used data from the multiplex peptide array, for ACPA fine-specificities: CEP-
1, Cit-fib36-52 and cfc1-cyc. Cut-off values for these antibody responses were set based on 198 
population-based controls from the NSHDS and the Maternity cohorts. 
  
3.5 GENERATION OF HUMAN MONOCLONAL ANTIBODIES   
In Study IV, we analysed 218 human monoclonal antibodies for reactivity against 
CPP3/RPP3. These antibodies had been generated previously in the lab by in vitro cloning 
[127-130]. Briefly, memory or plasma B cells were isolated from RA blood, synovial tissue 
or synovial membrane, and subsequently single cell sorted into PCR plates. Immunoglobulin 
cDNA was synthesized and amplified for individual Ig heavy (H) and light (L) (κ or λ) chain 
genes by reverse transcriptone-PCR, using primers previously described [131]. Matching IgH 
(γ) and Igκ/Igλ amplicons were sequenced (Eurofins MWG Operon) and compared against 
germline sequences using IgBLAST and IMGT/V-quest, in order to determine Ig gene 
usage, complementary determining region 3 (CDR3) features, and number of variable (V) 
gene usage. Immunoglobulin genes were subsequently cloned into human Igγ1, Igκ, or Igλ 
IgG expression vectors, and the vectors were transformed into DH5α bacteria (Gibco 
Invitrogen) before isolated by NucleoSpin plasmid DNA purification kits (Macherey-
Nagel). Recombinant monoclonal antibodies (IgG1) were produced in the Expi293 system 
(Thermo Fisher Scientific) with transient transfection using PEI-max [132], and purified on 
Protein G Fast Flow Sepharose, (GE Healthcare Life Sciences).  
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3.6 STATISTICAL METHODS  
Continuous data were compared using the non-parametric Mann–Whitney U-test for 
independent groups (Study I-IV), or Wilcoxon signed rank test including two groups, or 
Kruskal–Wallis test including several groups (Study III). For categorical data, the chi-
square test or Fisher’s exact test was used (Study III). Correlation analyses were performed 
using Spearman’s rank correlation coefficient (Study II and III), or Pearson correlation 
(using R v. 3.3.3) (Study IV). Associations between RA risk factors (i.e. smoking, HLA 
DRB1 SE and PTPN22) and presence of different antibodies in different RA subsets were 
calculated using unconditional logistic regression models with unexposed cases and/or 
controls as reference group, and presented as odds ratios (OR) with 95% confidence intervals 
(CI). Analyses were adjusted for age, gender and residential area (Study I, II and IV), or age 
and gender (Study III). Interaction was defined as departure from additivity of effects 
[133], and was evaluated between different RA risk factors in different subsets of RA 
(Study I-III). The attributable proportion due to interaction (AP) was calculated together 
with 95% CI, as previously described [134]. The AP value between two interacting factors 
reflects the joint effect beyond the sum of the independent effects [135]. All statistical 
analyses were performed using GraphPad Prism6 or SAS (version 9.1 or higher) (Study I, 
II and IV), or SPSS 23.0 software (Chicago, IL, USA) (Study III). P-values ≤0.05 were 
considered statistically significant. 
 
3.7 METHODS NOT INCLUDED IN SUDY I-IV  
3.7.1 ACPA purification 
For use in both in vitro and in vivo experiments, polyclonal ACPA IgG was purified from 
highly CCP2-positive plasma samples of patients with RA. Purification was done through 
affinity chromatography using columns with the CCP2 peptides (donated by Euro-
Diognostica AB) coupled to Sepharose beads. In brief, plasma samples were first centrifuged 
and diluted in PBS, before the IgG fraction was isolated on Protein G columns. The IgG 
fraction was then put on the CCP2 column, and the anti-CCP2 IgG was eluted and 
concentrated, followed by buffer exchanging to PBS. The CCP2-column IgG flow-through 
(FT) fraction was also collected, and used as a control in various in vitro and in vivo 
experiments where the purified ACPAs were further investigated. The ACPA purification 
method and related data was presented in Study V: “Affinity purified anti-citrullinated 
protein/peptide antibodies target antigens expressed in the rheumatoid joint” (Study V is not 
included in the thesis) [136].  
3.7.2 Western blot  
The ACPA and FT pools described above, were used in Western blot experiments: initially, 
to investigate their reactivity against citrullinated RA candidate autoantigens (α-enolase, 
vimentin and fibrinogen) and non-citrullinated counterparts (Study V), and subsequently to 
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study cross-reactivity with carbamylated proteins (α-enolase and fibrinogen) in Study VI: 
“Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind 
citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies” 
(Study VI is not included in the thesis) [137]. In addition, in an ongoing study, the 
ACPA/FT pools as well as the monoclonal ACPAs described above are being used for 
blotting P.gin lysates as well as lysates of arthritic mouse joints, in order to detect relevant 
ACPA targets. Briefly, modified and non-modified proteins (or P.gin/mouse joint lysates) 
were separated on NuPAGE Bis-Tris 4-20% gels by electrophoresis, and transferred to 
nitrocellulose membranes. After blocking (5% milk in TBS/0.05% Tween), membranes 
were incubated over night at 4°C with purified ACPA/FT, or monoclonal antibodies (all at 
1 or 2µg/ml), or the secondary antibody alone. As a secondary detecting antibody, HRP-
conjugated goat-anti human IgG was used (diluted 1:10,000) for 1h at RT. Detection of 
bound antibodies was visualized using the ECL chemiluminescence method. 
3.7.3 In vitro generation of citrullinated proteins  
Citrullination of the proteins used in the immunoblotting experiments described above was 
performed in vitro, by incubating proteins (α-enolase, vimentin and fibrinogen) with the 
rabbit skeletal PAD2 enzyme (Sigma, St. Louis, MO, USA) at a protein concentration of 
1mg/ml, and an enzyme concentration of 2U/mg protein, in PAD buffer (100 mM Tris, 10 
mM CaCl2, 5 mM dithiothreitol (DTT), pH 7.6) for 2h at 37° C. Citrullination was stopped 
by adding 20mM EDTA, followed by dialysis to calcium-free PBS. Citrullination was 
confirmed by mass spectrometry. 
3.7.4 Animal experiments  
In an ongoing study, aimed at investigating the effect of P.gin and ACPA on arthritis and 
pain development, we have used adult male BALB/c mice. In a pilot experiment, mice were 
injected intraarticularly with P.gin LPS at three different doses (0.5 µg, 1.5 µg and 3 µg). 
Acute arthritis (paw swelling/oedema) was scored by measuring paw thickness using a 
digital caliper for up to 6 days post injection (p.i.). Mice were sacrificed at the peak of 
inflammation (around day 2 p.i.), or when inflammation had subsided (day 6 p.i.). Mice 
were bled, serum was collected, and paws/ankles were frozen. In order to determine the 
optimal time point for subsequent ACPA transfer, i.e. when joint inflammation - and more 
importantly joint citrullination - was at its peak, presence of citrullinated proteins was 
examined by Western blot using the ACPA/FT pool or monoclonal antibodies, followed by 
mass spectrometry. As a positive control we used paws from severely arthritic mice, and as 
negative control, we used contra lateral paws, or paws from naïve mice.  
To assess pain during the experiment, we used the mechanical sensitivity test. Briefly, after 
acclimatization on the top of a mesh-like surface, optiHair filaments were applied under 
each paw until buckling of the hair filament was observed. Spontaneous withdrawal within 
three seconds was considered a positive response; 50% withdrawal was calculated using 
Dixon’s up-down method [16]. 
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3.7.5 Protein extraction  
Proteins from the mouse joints (bone and soft tissue) were extracted from P.gin LPS-injected 
paws and the contralateral paws, as well as from naïve mice and severely arthritic mouse 
paws. For this, we used a lysis buffer containing 150mM NaCl, 1mM EDTA, 50mM Tris and 
1% SDS, followed by sonication and centrifugation. Supernatants were collected and the 
protein concentration was determined using the Micro BCA assay. Samples were stored at -
80°C until further analysis. 
 
3.8 ETHICAL CONSIDERATIONS  
This PhD project has been aimed at increasing our understanding for the aetiology of RA, 
in order to develop better treatments for patients, and potentially a cure in the future, as 
well as to identify preventive strategies. To achieve this, we have used patient material, and 
in the ongoing study, also experimental animals.  
We have ethical permits for all studies described in this PhD thesis: from the regional ethics 
review board at Karolinska Institutet, Stockholm (Study I, II and IV), as well as the 
regional ethics review board in Umeå, Department of Medical Research (Study III), and 
for the ongoing animal study, from the local ethical committee for animal experiments in 
Stockholm. Biological samples were collected from patients and controls with informed 
consent. Ethical considerations included the protection of privacy and handling of personal 
data, which was done in accordance with the Swedish Law: Personuppgiftslagen (PUL). 
Information was stored behind the Karolinska University Hospital’s network firewall. All 
studies were conducted in compliance with the Declaration of Helsinki [122]. 
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4 RESULTS AND DISCUSSION  
4.1 STUDY I  
In Study I, we have investigated the fine-specificity of the ACPA response in relation to 
known RA risk factors: HLA-DRB1 SE, PTPN22 polymorphism and cigarette smoking. 
When this study was initiated, it was known that SE mainly associated with CCP2-positive 
RA, and that PTPN22 and cigarette smoking each interacted with SE to strengthen this 
association [11, 71]. It had also recently been shown that anti-CCP2 antibodies are a 
collection of ACPAs containing overlapping and non-overlapping reactivities [138]. 
Moreover, that the fine-specificity of the ACPA response is influenced by SE [139]. Our 
study was performed to further define which ACPA fine-specificities were associated with 
SE, PTPN22 and smoking. 
The study population comprised 1985 early RA cases and 2252 matched controls from the 
Swedish population-based case-control cohort EIRA. ACPAs specific for epitopes on 
citrullinated candidate autoantigens: α-enolase (CEP-1), vimentin (Cit-vim60-75), fibrinogen 
(Cit-fib36-52), and collagen type II (Cit-C1) were measured by in-house peptide ELISAs. 
Cross-reactivity between antibodies was investigated by peptide absorption experiments. 
Data on CCP2 status, genotype and smoking habits had been generated/collected previously, 
and were retrieved from the EIRA database. Associations between risk factors and specific 
ACPAs were calculated by logistic regression analysis, and presented as OR, with 95% CI.   
Presence of different ACPA fine-specificities (35% CEP-1-positive, 37% Cit-vim-positive, 
28% Cit-fib-positive and 37% Cit-C1-positive) overlapped to a large extent. Still 17 distinct 
RA subsets could be identified based on their different ACPA fine-specificity profiles. Data 
from the peptide-absorption studies suggested only limited cross-reactivity between these 
different ACPA fine-specificities. However, it should be mentioned that more recent studies, 
performed using monoclonal ACPAs, suggest a much broader cross-reactivity pattern for 
ACPAs (personal communication, Professor Vivianne Malmström). Our study could confirm 
the well-established association between SE and CCP2-positive RA, and when dividing the 
CCP2-positive subset further, based on the different ACPA fine-specificities, we found 
substantial differences. The strongest SE-association was identified for the subset of RA with 
antibodies targeting CEP-1 or Cit-vim, while no association was observed for Cit-fib-positive 
RA, and only a weak association was found for the Cit-C1-positive subset. Highest OR (49.6) 
was identified for the CEP-1/Cit-vim double positive subset, which could be compared to an 
OR of only 2.5 for the Cit-fib/Cit-C1 double positive subset. Notably, anti-CCP IgG levels 
were significantly higher in Cit-fib+/Cit-C1+ RA, compared to CEP-1+/Cit-vim+ RA, 
suggesting that SE mainly influences the fine-specificity of the ACPA response, rather than 
total anti-CCP IgG levels. Also the combined effect of SE, PTPN22 and smoking associated 
primarily with the subset of RA characterised by anti-CEP-1 antibodies, and to a lesser extent 
also anti-Cit-vim antibodies, while these risk factors had no specific association with 
antibodies against Cit-fib or Cit-C1 (beyond the effect conveyed by CCP2) (Figure 4). 
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Figure 4 Combined effects of SE, PTPN22 
and smoking  on disease risk in different RA 
subsets. RA subsets were defined based on 
presence/absence of one ACPA fine-
specificity without taking into account which 
other ACPA fine-specificities may be present 
simultaneously. White bars = subsets negative 
for the ACPA fine-specificity and negative for 
CCP2 (-/-); grey bars = subsets negative  for 
the ACPA fine-specificity but positive for 
CCP2 (-/+); black bars = subsets positive for 
the ACPA fine-specificity but where the 
CCP2 status was not considered (+/ + or -). 
The asterisk indicate p < 0.05.  
 
This study still provides the most comprehensive picture to date of how SE, PTPN22 and 
smoking are associated with the presence of specific ACPAs rather than anti-CCP2 antibody 
levels, suggesting that their production may be governed by partly different mechanisms. 
Important to note is also that the CCP2 assay, commonly used in clinics, does not capture all 
ACPA fine-specificities, as 18% of the CCP2-negative patients were in fact ACPA-positive, 
suggesting that extended ACPA screening (in addition to the CCP2 test), should be 
considered. The antigens investigated in our study are likely to represent physiological targets 
of the ACPA response, as they are expressed in the rheumatoid joint [47, 55, 60, 140].  
However, they should not be considered the only “true” autoantigens in RA. Approximately 
14% of the CCP2-positive patients in our study were negative for the four ACPA fine-
specificities investigated, indicating the presence of yet other ACPA fine-specificities, not 
investigated here. Since our study was conducted, a number of other candidate autoantigens 
have indeed been described, including citrullinated histones [38, 64] and citrullinated         
tenascin C [39], as well as citrullinated viral and bacterial antigens [46, 64, 105]. 
 
4.2 STUDY II 
Study II was aimed at investigating the role of the oral pathogen Porphyromonas gingivalis 
in RA etiology, by measuring antibodies to arginine gingipain B (RgpB), the most potent 
virulence factor of P.gin, and to analyse this antibody response in relation to the presence of 
autoantibodies (in particular ACPAs) and RA risk factors (i.e. SE, PTPN22 and smoking). 
The basis for this study was the reported epidemiological association between PD and RA, 
Impact of HLA-DRB1 SE on disease risk in different RA subsets
The results described above may be infl uenced by the coexis-
tence of multiple ACPA fi ne specifi cities. We next investigated 
the four RA subsets which were defi ned by the sole presence of 
one ACPA fi ne specifi city—that is, the subsets that were ‘single 
positive’ for anti-CEP-1, anti-Cit-vim, anti-Cit-fi b or anti-Cit-C1 
antibodies. In this analysis we focused on HLA-DRB1 SE, the 
risk factor with the strongest impact. We found a relatively 
strong association of HLA-DRB1 SE with CEP-1 positive RA (OR 
5.1) as well as with Cit-vim positive disease (OR 6.0) but not 
with Cit-fi b positive disease (OR 1.4), and the association with 
Cit-C1 positive RA was weak (OR 1.6) (table 1). A signifi cant 
association of HLA-DRB1 SE (OR 2.5, 95% CI 1.8 to 3.6) could 
also be observed with the subset that was positive for CCP but 
negative for all four ACPA fi ne specifi cities (data not shown).
We then studied the effect of being positive for different 
combinations of two ACPA fi ne specifi cities as the impact of 
HLA-DRB1 SE may differ between subsets defi ned by specifi c 
combinations of non-cross-reactive ACPAs. The strongest infl u-
ence of HLA-DRB1 SE was identifi ed for CEP-1/Cit-vim double-
positive RA (OR 49.6) which could be compared with an OR 
of 2.5 for the association with Cit-fi b/Cit-C1 double-positive 
RA. Interestingly, anti-CCP antibody levels were higher in the 
Cit-fi b/Cit-C1 double-positive subset than in the CEP-1/Cit-vim 
double-positive subset, suggesting that HLA-DRB1 SE mainly 
infl uence the fi ne specifi city of the ACPA response rather than 
anti-CCP levels (see fi gure 2 in online supplement).
disease OR 8.9, fi gure 3B). Subsets defi ned by antibodies to Cit-
fi b or Cit-C1, on the other hand, did not demonstrate such spe-
cifi c associations beyond the effect of CCP (OR 15.6 vs 12.9 for 
Cit-fi b and 10.0 vs 13.8 for Cit-C1; fi gure 3C,D).
Figure 3 Combined effect of HLA-DRB1 SE, PTPN22 and smoking 
on disease risk in different subsets of rheumatoid arthritis (RA). ORs 
with 95% CI were calculated using unconditional logistic regression 
analysis by comparing individuals positive for the risk factors with 
individuals who were negative. RA subsets were defi ned based on the 
presence or absence of one anticitrullinated protein/peptide antibody 
(ACPA) fi ne specifi city without taking into account which other ACPA 
fi ne specifi cities may be present simultaneously. Antibody responses to 
citrullinated peptides from (A) α-enolase (CEP-1), (B) vi entin (Cit-vim), 
(C) fi brinogen (Cit-fi b) and (D) collagen type II (Cit-C1). White bars show 
subsets negative for the ACPA fi ne specifi city and negative for cyclic 
citrullinated peptide (CCP) (−/−); grey bars show subsets negative 
for the ACPA fi ne specifi city but positive for CCP (−/+); black bars 
show subsets positive for the ACPA fi ne specifi city but where the CCP 
status was not considered (+/ + or −). 95% CIs for −/+ and +/+ 
or − subsets are: (A) 4.58 to 13.53 vs 19.07 to 79.97; (B) 5.03 to 15.68 
vs 13.95 to 47.02; (C) 7.55 to 0 vs 8.51 to 4; (D) 7.55 to 9 vs 6.07 to 9. 
Asterisks indicate non-overlapping 95% CI. 
Table 1 ORs for disease risk in different subsets of rheumatoid arthritis 
in carriers of HLA-DRB1 shared epitope (SE) compared with non-carriers
ACPA CEP-1/Cit-vim/Cit-fib/Cit-C1
HLA-DRB1 SE
OR* 95% CIAny None
Control 
group
NA 643 635 1.0 Ref
Case 
groups
+/−/−/− 59 12 5.1 2.7 to 9.5
−/+/−/− 108 18 6.0 3.6 to 10.0
−/−/+/− 28 21 1.4 0.75 to 2.5
−/−/−/+ 91 57 1.6 1.11 to 2.3
+/+/−/− 97 2 49.6 12.1 to 202.5
+/−/+/− 21 7 3.2 1.3 to 7.6
+/−/−/+ 43 3 15.0 4.6 to 49.0
−/+/+/− 18 8 2.3 1.0 to 5.4
−/+/−/+ 69 10 6.9 3.5 to 13.6
−/−/+/+ 36 14 2.5 1.3 to 4.7
*Adjusted for age, gender and residence area.
ACPA, anticitrullinated protein/peptide antibodies.
Table 2 ORs for disease risk in different subsets of rheumatoid arthritis 
in subjects exposed to different combinations of HLA-DRB1 shared 
epitope (SE) and smoking compared with non-exposed subjects
CEP-1/Cit-vim/
Cit-C1
HLA-DBR1 
SE Smoking Cases/controls OR* 95% CI
−/−/− − − 115/228 1 Ref
−/−/− + − 176/244 1.4 1.1 to 1.9
−/−/− − + 173/316 1.1 0.8 to 1.5
−/−/− + + 233/315 1.6 1.2 to 2.1
+/−/− − − 3/228 1 Ref
+/−/− + − 25/244 8 2.4 to 27.0
+/−/− − + 13/316 3.3 0.9 to 11.9
+/−/− + + 46/315 12.5 3.8 to 40.9
−/+/− − − 7/228 1 Ref
−/+/− + − 42/244 5.8 2.5 to 13.3
−/+/− − + 15/316 1.7 0.7 to 4.3
−/+/− + + 64/315 7.3 3.2 to 16.4
−/−/+ − − 35/228 1 Ref
−/−/+ + − 41/244 1.1 0.7 to 1.8
−/−/+ − + 31/316 0.6 0.4 to 1.1
−/−/+ + + 68/315 1.4 0.9 to 2.3
+/+/− − − 5/228 1 Ref
+/+/− + − 29/244 5.5 2.1 to 14.5
+/+/− − + 7/316 1 0.3 to 3.3
+/+/− + + 118/315 18.4 7.3 to 46.1
+/−/+ − − 3/228 1 Ref
+/−/+ + − 25/244 7.7 2.3 to 26.1
+/−/+ − + 11/316 2.7 0.7 to 10.0
+/−/+ + + 65/315 17.2 5.3 to 55.8
−/+/+ − − 7/228 1 Ref
−/+/+ + − 27/244 3.5 1.5 to 8.4
−/+/+ − + 10/316 1 0.4 to 2.8
−/+/+ + + 52/315 5.6 2.5 to 12.7
+/+/+ − − 6/228 1 Ref
+/+/+ + − 54/244 8.5 3.6 to 20.1
+/+/+ − + 14/316 1.6 0.6 to 4.3
+/+/+ + + 189/315 23.3 10.1 to 53.7
*Adjusted for age, gender and residential area.
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now confirmed in a meta-analysis [95], and more specifically, the hypothesis first put forward 
by Rosenstein and collagues, that ACPA-positive RA is precipitated by the oral pathogen 
P.gin [107].  
As in Study I, we used the EIRA cohort for these analyses. The RgpB protein was purified 
from P.gin, and anti-RgpB IgG was measured by in-house protein ELISA in 1975 RA cases 
and 377 controls, as well as in 65 patients with PD and 59 periodontally healthy controls. 
Data on genetics, smoking habits and autoantibodies were retrieved from the EIRA database, 
and associations with anti-RgpB IgG were calculated by unconditional logistic regression 
analyses, and presented as OR, with 95% CI.  
We identified a significant association between elevated anti-RgpB antibodies and RA, in 
particular ACPA-positive RA (Table 4). Interestingly, this association was even stronger than 
the well-known association between smoking and RA.  
 
Table 4 Association between elevated anti-RgpB IgG levels and RA in 
subgroups of patients, divided according to the presence/absence of ACPAs 
 
 
Moreover, we found that anti-RgpB antibody levels were significantly elevated in PD 
patients compared to non-PD controls (p<0.0001); in RA compared to non-RA controls 
(p<0.0001); and in ACPA-positive RA compared to ACPA-negative RA (p<0.003). Our data 
are thus in line with a number of previous reports, as well as a recent meta-analysis (which 
also includes our own study) [114]. Based on ACPA fine-specificity data from Study I, we 
also investigated whether the anti-RgpB IgG response was specifically associated with 
antibodies to CEP-1, Cit-vim60-75, Cit-fib36-52 or Cit-C1, as well as antibodies to carbamylated 
fibrinogen and RF. However, we could not detect any specific association with any of these 
antibodies, beyond the association with CCP2-positive RA. Importantly, there was no 
association between smoking and increased anti-RgpB IgG levels, despite smoking being a 
risk factor also for PD. Instead, smoking and elevated anti-RgpB IgG levels were 
independently associated with ACPA-positive RA. The association between anti-RgpB 
antibodies and RA was also independent of SE and PTPN22, but interestingly, statistically 
periodontitis and without RA (32–34), we also screened
the periodontitis patients and the controls without peri-
odontitis in our study for the presence of ACPAs, but no
ACPA response could be detected in any of these individ-
uals (data not shown).
To further investigate the association between
the ACPA response and the anti-RgpB antibody
response in RA, we next examined the fine specificity of
the ACPA response in more detail. Anti-RgpB IgG was
analyzed in different subsets of RA patients, defined by
the presence/absence of anti–CEP-1, anti–Cit-vimentin60–75,
anti–Cit-fibrinoge 36–52, or anti–Cit-C1 antibodies. These
analyses were performed in relation to anti-CCP2 status,
which was used as a surrogate marker for the overall
ACPA response. None of the investigated ACPA fine spe-
cificities revealed any significant association with anti-
RgpB IgG beyond the effect of the overall ACPA
response (as measured using the CCP2 test). Similar ana-
lyses based on RF status or on the presence/absence of
antibodies to carbamylated fibrinogen showed no differ-
ences between subsets (further information is available
upon request from the corresponding authors).
The anti-RgpB IgG response in relation to ciga-
rette smoking. Since periodontitis patients showed ele-
vated anti-RgpB antibody levels (Figure 1A), and since
smoking is a well-established risk factor for periodontitis
(13), we first examined the relationship between smok-
ing status and anti-RgpB IgG exposure in the EIRA
study. Potentially, the positive association between anti-
RgpB IgG and ACPA-p sitive RA (Figure 1C and
Table 1) could result from smoking as a confounding
factor. However, we could not identify any association
between smoking and elevated anti-RgpB IgG levels in
RA patients in the EIRA study. Among controls in the
EIRA study, we could even observe an inverse associa-
tion (further information is available upon request from
the corresponding authors). Instead, smoking and ele-
vated anti-RgpB IgG levels ere i dependently associ-
ated with ACPA-positive RA, with ORs of 1.36 (95%
CI 1.01, 1.83) and 2.40 (95% CI 1.29, 4.46), respectively.
Moreover, a significant additive interaction was observed
betwe n the 2 factors, with an OR of 5.35 (95% CI 3.07,
9.33) and a significant attributable proportion due to
interaction of 0.48 (95% CI 0.12, 0.85). In ACPA-
negative RA, however, neither smoking nor elevated
anti-RgpB IgG levels showed any independent associa-
tions, although an additive effect could be observed, but
there was no interaction (Table 3).
The anti-RgpB IgG response in relation to RA risk
genes. We also investigated the association between ele-
vated anti-RgpB IgG levels and HLA–DRB1 SE alleles
and PTPN22 polymorphism. None of these genetic risk
Table 1. Association between elevated anti-RgpB IgG levels and RA in subgroups of patients, divided
according to the presence/absence of ACPAs*
Subgroup
Anti-RgpB IgG
negative, no. (%)
Anti-RgpB IgG
positive, no. (%) OR (95% CI)†
Controls 341 (90.45) 36 (9.55) 1.0 (referent)
All RA patients 1,518 (76.90) 456 (23.10) 2.96 (2.00, 4.37)
ACPA-positive RA patients 1,041 (75.38) 340 (24.62) 3.24 (2.18, 4.81)
ACPA-negative RA patients 477 (80.44) 116 (19.56) 2.35 (1.51, 3.65)
* Anti-RgpB 5 anti–arginine gingipain type B; RA5 rheumatoid arthritis; ACPAs5 anti–citrullinated protein
antibodies; OR5odds ratio; 95% CI5 95% confidence interval.
† Adjusted for age, sex, and residential area.
Table 2. Association between smoking and RA in subgroups of patients, divided according to the presence/
absence of ACPAs*
Subgroup
Never smoked,
no. (%)
Ever smoked,
no. (%) OR (95% CI)†
Controls 137 (36.63) 237 (63.37) 1.0 (referent)
All RA patients 603 (30.61) 1,367 (69.39) 1.37 (1.07, 1.74)
ACPA-positive RA patients 331 (26.91) 899 (73.09) 1.67 (1.29, 2.17)
ACPA-negative RA patients 270 (37.60) 448 (62.40) 1.00 (0.75, 1.32)
* RA5 rheumatoid arthritis; ACPAs5 anti–citrullinated protein antibodies; OR5odds ratio; 95% CI5 95%
confidence interval.
† Adjusted for age, sex, and residential area.
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significant interactions between elevated anti-RgpB IgG levels and both SE and smoking was 
identified for ACPA-positive RA (not for ACPA-negative RA).  
In a recent study from our lab, it was shown that 33% of RA patients and controls in EIRA 
suffer from PD [113], while in the present study we show that 23% of RA patients, but only 
9.4% of controls have elevated anti-RgpB IgG levels. This apparent contradiction could be 
related to the investigation of early RA in our study, versus established RA in the other study 
(as investigations of PD status was performed years after inclusion in EIRA). Alternatively, 
presence of anti-RgpB antibodies should not be considered as surrogate marker for PD, as 
anti-RgpB IgG could reflect a historical P.gin infection, and PD could also be caused by other 
pathogens than P.gin, and P.gin infection may not always cause PD. Moreover, different 
P.gin strains show differences in expression of virulence factors [141, 142] and a recent study 
could demonstrate that only some P.gin strains express a P.PAD enzyme capable of peptidyl-
citrullination [106]. Taken together, Study II supports a causative role for P.gin in ACPA-
positive RA etiology, and we propose that P.gin could account for the previously reported 
link between chronic PD and RA.  
 
4.3 STUDY III  
Building on data from Study II, where we identified an association between elevated anti-
P.gin antibody levels and RA, Study III examines whether anti-P.gin antibodies pre-date RA 
symptom onset and ACPA production. In order to do this, we analysed the presence of anti-
P.gin antibodies in plasma/serum samples collected before (and after) clinical onset of RA. 
This study included 251 pre-RA/RA cases - who had donated in total 422 blood samples 
before symptom onset (median: 5.2 years; interquartile range 6.2) - and 198 population-based 
non-RA controls, from the Biobank of Northern Sweden Health and Disease Study (NSHDS) 
as well as the Maternity cohort. Antibodies to two P.gin-specific antigens were analysed by 
ELISA: RgpB and CPP3 (a citrullinated peptide derived from P.PAD, that has been identified 
as an immunodominant epitope in autocitrullinated P.PAD) [105] . Data on genetics, 
smoking habits and autoantibodies were retrieved from a database. Continuous data were 
compared using Mann–Whitney U-test/Wilcoxon signed rank test (including two groups), 
and Kruskal–Wallis (including several groups). Chi-square test or Fisher’s exact test was 
used for categorical data, Spearman's rank correlation was used for correlation analysis, and 
logistic regression was used to calculate associations between antibodies and risk factors. 
This study showed significantly elevated anti-RgpB antibody levels in pre-symptomatic 
individuals and in RA patients, compared to controls (p < 0.001); mean concentration of anti-
RgpB IgG in pre-symptomatic individuals exceeded that of controls 12 years before symptom 
onset. Antibodies against CPP3 were detected in 6.8% of pre-symptomatic individuals and in 
7.8% of RA patients, with significantly increased levels compared to controls (p < 0.001); 
mean concentration of anti-CPP3 IgG in pre-symptomatic individuals exceeded that of 
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controls eight years before symptom onset. Anti-RgpB IgG levels were stable in pre-
symptomatic individuals with a significant increase over time when analysing individuals 
with at least four consecutive pre-dating samples (p < 0.05), and a non-significant decline (p 
< 0.088) after RA diagnosis, while anti-CPP3 IgG levels followed the classical ACPA 
response [143], with increasing concentrations over time (Figure 5).  
 
 
 
 
 
 
 
Figure 5 Anti-P.gin antibody responses during the pre-dating time until the onset of symptoms of RA. 
Logarithmic mean antibody concentrations during 2-year periods of anti-RgpB and anti-CPP3 antibodies are 
shown for pre-symptomatic individuals (n=422), patients with RA (n=192), and controls (n = 198).  
 
Increased anti-RgpB antibody levels appeared to precede the classical ACPA response, and a 
(weak) correlation between anti-RgpB and the ACPA response (measured as anti-CEP-1 
antibody concentrations) was observed. The median pre-dating time for anti-CPP3 antibody 
positivity was closer to RA onset (−3.42 years), when compared to the classical ACPA 
response (CCP2: −4.56 years). Notably though, we treated anti-CPP3 IgG as a classical 
ACPA, and therefore set cut-off for positivity based on reactivity among 198 non-RA 
controls, of unknown periodontal status. However, CPP3 is not an autoantigen, it is a 
bacterial peptide, with no sequence homology to human proteins. Hence, it is possible that the 
cut-off for positivity was set too low, as we did not have access to periodontally healthy 
controls. No cut-off for positivity was set for the anti-RgpB antibody response for this reason.  
Elevated anti-RgpB IgG levels (>75th percentile) were associated with being pre-
symptomatic, while anti-CPP3 IgG was associated with having RA (after adjustment for age, 
gender and SE, or PTPN22). No associations were identified between anti-P.gin antibodies 
and classical RA risk factors, in line with data from our Study I. However, SE in combination 
with anti-CPP3 IgG revealed a stronger association with both pre-RA and RA, than SE alone, 
and the same was observed for smoking and anti-CPP3 IgG in RA.  
It should be mentioned that a previous study failed to identify associations between anti-
RgpB or anti-CPP3 IgG and pre-RA [144], although other studies have shown elevated anti-
P.gin antibody levels in individuals at increased risk of developing RA [116, 117], and taken 
Fig. 2 Antibody responses during the pre-dating time until the time point for onset of symptoms of RA, from pre-symptomatic individuals who donated
multiple blood samples pre-dating the onset of symptoms of RA (n= 422) and from patients with RA (n= 192). Logarithmic mean concentrations during
2-year periods of anti-RgpB and anti-CPP3 antibodies in pre-symptomatic individuals, patients with RA and controls (n= 198) (a). Accumulated percentages
of antibody positivity for anti-CPP3, anti-CCP2, anti-cfibrinogenβ36-52 (cFibβ36-52), anti-CEP-1 (α-enolase) and anti-cfilaggrin (cFilaggrin) antibodies in
pre-symptomatic individuals and in patients with RA (b). 0 time point for onset of RA symptoms
Johansson et al. Arthritis Research & Therapy  (2016) 18:257 Page 2 of 2
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together, we conclude that our data from Study III further supports an etiological role for                
P. gingivalis in the development of RA.  
 
4.4 STUDY IV  
Study IV focuses on the antibody response to the P.PAD derived citrullinated peptide CPP3, 
which we found elevated in pre-symptomatic RA as well as in RA patients, when compared 
to population-based controls in Study III. In a similar manner as with the antibody response 
to RgpB (Study II), we set out the characterise the anti-CPP3 antibody response in relation to 
RA risk factors and the classical ACPA response in the EIRA cohort, in order to address the 
hypothesis that P.gin may be driving ACPA-production in a subset of RA. 
Presence of anti-CPP3 antibodies was analysed by ELISA, in 65 PD patients and 63 
periodontally healthy controls, and in 2859 RA cases and 370 non-RA controls using the 
ISAC multiplex array, also containing citrullinated peptides from five human proteins. In 
addition, 218 human monoclonal antibodies (generated in-house by recombinant expression 
of immunoglobulins from RA B cells) were screened for CPP3 reactivity. Data on CCP2 
status, genetics and smoking habits were retrieved from the EIRA database. Co-occurrence of 
anti-CPP3 antibodies with classical ACPA fine-specificities was investigated by pairwise 
Pearson’s correlation; associations with RA risk factors were calculated by logistic 
regression.  
Increased anti-CPP3 IgG levels were detected in PD compared to non-PD controls 
(p<0.0001), and this antibody response seemed to be citrulline-specific, since reactivity with 
the arginine-containing control peptide RPP3 was significantly lower. By using non-RA 
EIRA controls with unknown periodontal status to set cut-off for positivity, 11% of EIRA RA 
patients were anti-CPP3 antibody positive, and the majority was found within the             
CCP2-positive subset. Still, while the classical ACPAs showed high co-occurrence, anti-
CPP3 IgG showed only weak correlations to other ACPAs (with strongest correlation 
identified for anti-Cit-vim60-75 IgG), which may suggest partly different mechanisms for the 
production of anti-CPP3 IgG as compared to the classical ACPA response. Some support for 
this came from analyses of genetic risk factors, where anti-CPP3 IgG (unlike antibodies to 
CEP-1 and Cit-vim60-75) showed no specific association with SE or PTPN22. However, a 
significant association was identified between smoking and anti-CPP3 IgG. 
A total of four monoclonal antibodies derived from RA B cells, showed reactivity against 
CPP3, with low or no cross-reactivity against RPP3. Strikingly, one of these monoclonal 
antibodies (BVCA1:01A01) also bound CCP2, and Cit-vim60-75, demonstrating cross-
reactivity between bacterial and human citrullinated epitopes (Figure 6).  
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Figure 6 Reactivity of monoclonal antibodies derived from RA B cells. Four (out of 218) monoclonal antibodies 
showed reactivity against CPP3 in ELISA, with low or no reactivity against RPP3 (A). The monoclonal antibody 
with the strongest CPP3-reactivity (BVCA:01A01) also showed reactivity against citrullinated peptides derived 
from human proteins (in particular Cit-Vim60-75), when analysed on the peptide multiplex array (B). OD = optical 
density; AU = arbitrary units.  
 
Comparison of somatic mutations in the IgG V genes, revealed a higher number of mutations 
in BVCA1:01A01 than in the other CPP3-reactive monoclonal antibodies, suggesting 
extensive/repetitive autoantigen-driven activation of this B cell response. Based on our data, 
we speculate that an initial immune response against the CPP3 epitope of P.gin at some point 
cross-reacts with citrullinated human vimentin by mechanisms of molecular mimicry, and in 
SE-positive/PTPN22-positive individuals this may trigger activation of autoreactive T cells, 
clonal selection, affinity maturation and expansion of the ACPA response, in line with our 
etiological model presented in the Introduction (Figure 3). 
In light of the data from Study IV, we would like to re-phrase our discussion on the CPP3 
response in Study III, where we suggested that the anti-CPP3 antibody response: "rather than 
being P.gin specific, simply belongs to the generic ACPA response, or rather represents 
cross-reactivity with another citrullinated antigen". That conclusion was based on not finding 
a correlation between the anti-RgpB antibody response and the anti-CPP3 antibody response, 
and not finding an increased frequency of CPP3-positivity in pre-symptomatic individuals 
compared to controls. We now believe that this could (at least partly) be explained by the 
very high cut-off for CPP3-positivity used in the pre-RA study. That cut-off, as well as the 
cut-off used for the EIRA cohort in Study IV, was based on non-RA controls with unknown 
periodontal status. In study IV, we also show elevated anti-CPP3 IgG levels in approximately 
half of the PD patients, when compared to periodontally healthy controls, and moreover, that 
this antibody response is citrulline-specific. Hence, with a lower cut-off for positivity, more 
pre-symptomatic individuals would have been positive in Study III, but at the same time 
more population-based controls would have been positive. In an additional experiment, we 
A              B 	
	
 
     
C      CPP3    AKTDSYWT-X-DYTGWFAMYD 
     Cit-Vim60-75              VYAT-X-SSAV-X-L-X-SSVP 
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have now compared the anti-CPP3/RPP3 antibody response in PD (n=65) and non-PD 
(n=63), with CCP2-positive (n=101) and CCP2-negative RA (n=99), as well as non-RA 
controls (n=120), (Figure 7). 
 
A         B 
 
Figure 7 The antibody response to CPP3 (A) and RPP3 (B) in PD, CCP2-positive RA, CCP2-negative RA, and 
non-RA controls, in comparison to non-PD controls. The dotted line indicates cut-off for anti-CPP3/RPP3 IgG 
positivity. The percentages in graph A indicate the frequency of anti-CPP3 IgG positive individuals in each 
subset. AU = arbitrary units; HC = healthy controls (i.e. non-RA controls). 
Setting a cut-off value at 10AU, based on CPP3-reactivity among non-PD controls, this 
analysis shows that 37% of non-RA controls have elevated anti-CPP3 IgG levels, which 
should be compared to 50% of CCP2-positive RA, and 65% of PD patients. Importantly, anti-
RPP3 IgG levels were significantly lower in all subsets investigated, demonstrating that the 
antibody response to this P.gin epitope is citrulline-specific. To our knowledge, this is the 
first substantial ACPA response described in non-RA individuals. Note that high anti-CPP3 
IgG levels (>25AU) were almost exclusively detected in CCP2-positive RA, and correspond 
to approximately 10% of all RA patients, which is similar as in Study III where 7.8% were 
anti-CPP3 antibody positive, and Study IV where 11% were anti-CPP3 antibody positive.   
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5 CONCLUSIONS AND FUTURE PERSPECTIVES  
 
In Study I we provided novel data concerning the relationships between specific 
autoimmune reactions and genetic and environmental determinants for the risk of 
developing RA, with the overall conclusion that HLA-DRB1 SE alleles, PTPN22 
polymorphism and cigarette smoking are associated with the presence of specific ACPA-
reactivities rather than the magnitude of the ACPA response measured as total levels of 
anti-CCP2 antibodies. Our data thus emphasize the complexity of the gene–environment 
influence on ACPA-positive RA, and suggest that different ACPA fine-specificities may 
develop through partly different mechanisms.  
Today, multiplex assays, like the one used by us in Study IV [126], and protein/tissue 
arrays - rather than single-antigen based ELISAs - are being used for studies of the broad 
ACPA response, where hundreds or even thousands of citrullinated epitopes can be 
analysed simultaneously. These types of studies will better pinpoint which proteins and 
specific epitopes are targeted in vivo, and at what time point during the disease process. 
Ongoing studies also focus on the hypothesis that different citrullinated peptides are 
presented by different SE-alleles. Recently after our study was published, another study 
was published, demonstrating that specific amino acids in specific positions in the peptide 
binding groove of the MHC class II molecule determine the association with ACPA-
positive RA [145].  Extended studies of the ACPA fine-specificity response in relation to 
different SE alleles/different amino acids in the peptide-binding groove, as well as 
investigations of T cell responses to citrullinated peptides, will help uncover disease 
pathways in ACPA-positive RA, and form the basis for the development of novel therapies. 
Study II, III and IV all focused on the etiological model that the periodontal bacteria          
P. gingivalis triggers ACPA-positive RA. The basis for this hypothesis is the unique feature 
of P.gin to express its own PAD enzyme, which is capable of the formation of new 
citrullinated antigens in the gum mucosa, and potentially also in the joint, since P.gin DNA 
has been detected in rheumatic joints [146]. Our studies clearly show that the antibody 
response to P.gin is associated with RA, in particular ACPA-positive RA. Since EIRA 
comprise patients with DMARD-naïve early RA, and since anti-P.gin antibody levels were 
found elevated also in blood samples collected before the onset of clinical RA, we do not 
think that this antibody response is a consequence of RA. Both antigens used in these 
studies, RgpB and CPP3, represents P.gin-specific antigens, hence we propose that anti-
RgpB and anti-CPP3 antibodies could be used as surrogate markers for P.gin infection, past 
or present, and we conclude that our data support a causative role for P.gingivalis in the 
development of ACPA-positive RA. Moreover, that P.gin could be an etiological factor 
explaining the epidemiological link between PD and RA [95].   
The most intriguing findings presented in this thesis were: I) the citrulline-specific antibody 
response against an epitope on P.PAD in non-RA individuals, and II) the cross-reactivity 
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between P.gin CPP3 and human Cit-vim60-75 on a monoclonal antibody level. These data fit 
very well into the etiological model presented in figure 3 in the Introduction: antibodies 
against P.gin develop in response to P.gin infection, and if the P.gin strain expresses a 
P.PAD enzyme capable of autocitrullination, the CPP3 epitope may be exposed and trigger 
a CPP3-specific antibody response, which could cross-react with citrullinated epitopes on 
human proteins by mechanisms of molecular mimicry. HLA-DRB1 SE and PTPN22 were 
not specifically associated with the anti-CPP3 antibody response, but with the anti-Cit-
vim60-75 antibody response, suggesting that SE and PTPN22 are not required for the anti-
CPP3 antibody response, but increase the risk for the autoimmune ACPA response, and 
subsequently RA, to develop. The etiological model then propose that the expanded ACPA 
response eventually target citrullinated proteins exposed in the joint, form immune 
complexes, activate osteoclasts, and recruit neutrophils which undergo NETosis and release 
more PADs and citrullinated proteins, and this vicious circle ultimately cause                  
chronic RA [3, 8]. 
In order to further investigate this hypothesis, and to more directly study the involvement of 
ACPAs in arthritis induction, we aim to develop an animal model based on ACPA transfer, 
following intraarticular P.gin injection. This model is bypassing the first step in the 
aetiological hypothesis (i.e. the production of ACPA); rather it is focusing on the second 
stage (i.e. the ability of ACPA to mediate chronic arthritis). To this date, we have injected 
mice intraarticularly with P.gin LPS. This local insult induces a transient joint inflammation 
that lasts for approximately a week. However, the induction of local citrullination (evaluated 
by Western blot using human ACPAs and mass spectrometry) seems to be rather poor.  
Hence, we will use P.gin lysates in future experiments, as P.gin lysates will contain 
additional virulence factors, including P.PAD/autocitrullinated P.PAD. After P.gin 
intraarticular injection, we will transfer human ACPAs, starting with the CPP3/Cit-vim60-75 
cross-reactive monoclonal BVCA:01A01 antibody, which has the ability to bind both 
autocitrullinated P.PAD and citrullinated vimentin, which was one of the endogenously 
citrullinated proteins detected by mass spectrometry in the mouse joints. This type of 
experiment could provide more direct evidence for ACPA’s arthritogenic potential. 
As a concluding remark, all our studies clearly points towards an involvement of both 
smoking and oral infection in the development of RA, especially in genetically predisposed 
individuals. Hence, in future studies we will evaluate anti-CPP3 IgG as a potential 
serological marker for the identification of PD patients at increased risk of developing RA. 
Moreover, we should encourage individuals at risk to never start smoking and to go for 
regular dental/oral check-ups, in order to try to prevent the development of RA. 
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